Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase

Thomas Szekeres, Kamran Gharehbaghi, Monika Fritzer, Michael Woody, Arun Srivastava, Bart van't Riet, Hiremagalur N. Jayaram, Howard L. Elford

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of ribonucleotide reductase (EC 1.17.4.1) in extracts of L1210 cells by 50% (50% growth-inhibitory concentration, IC50) at 5 μM, whereas hydroxyurea, the only ribonucleotide reductase inhibitor in clinical use, exhibited an IC50 of 500 μM. Ribonucleotide reductase activity was also measured in situ by incubating L1210 cells for 24 h with trimidox at 7.5 μM, a concentration that inhibits cell proliferation by 50% (IC50) or at 100 μM for 2 h; these concentrations resulted in a decrease in enzyme activity to 22% and 50% of the control value, respectively. Trimidox and hydroxyurea were cytotoxic to L1210 cells with IC50 values of 7.5 and 50 μM, respectively. Versus ribonucleotide reductase, trimidox and hydroxyurea yielded IC50 values of 12 and 87 μM, respectively. A dose-dependent increase in life span was observed in mice bearing intraperitoneally transplanted L1210 tumors. Trimidox treatment (200 mg/kg; q1dx9) significantly increased the life span of mice bearing L1210 leukemia (by 82 in male mice and 112% in female mice). The antitumor activity appeared more pronounced in female mice than in male mice. Viewed in concert, these findings suggest that trimidox is a new and potent inhibitor of ribonucleotide reductase and that it is a promising candidate for the chemotherapy of cancer in humans.

Original languageEnglish
Pages (from-to)63-66
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume34
Issue number1
DOIs
StatePublished - Jan 1994

Fingerprint

Ribonucleotide Reductases
Inhibitory Concentration 50
3,4-dihydroxybenzohydroxamic acid
Hydroxyurea
Bearings (structural)
Leukemia L1210
Chemotherapy
Cell proliferation
Enzyme activity
Cell Extracts
3,4,5-trihydroxybenzamidoxime
Tumors
Neoplasms
Cell Proliferation
Drug Therapy
Enzymes
Growth

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Szekeres, T., Gharehbaghi, K., Fritzer, M., Woody, M., Srivastava, A., van't Riet, B., ... Elford, H. L. (1994). Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology, 34(1), 63-66. https://doi.org/10.1007/BF00686113

Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. / Szekeres, Thomas; Gharehbaghi, Kamran; Fritzer, Monika; Woody, Michael; Srivastava, Arun; van't Riet, Bart; Jayaram, Hiremagalur N.; Elford, Howard L.

In: Cancer Chemotherapy and Pharmacology, Vol. 34, No. 1, 01.1994, p. 63-66.

Research output: Contribution to journalArticle

Szekeres, T, Gharehbaghi, K, Fritzer, M, Woody, M, Srivastava, A, van't Riet, B, Jayaram, HN & Elford, HL 1994, 'Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase', Cancer Chemotherapy and Pharmacology, vol. 34, no. 1, pp. 63-66. https://doi.org/10.1007/BF00686113
Szekeres, Thomas ; Gharehbaghi, Kamran ; Fritzer, Monika ; Woody, Michael ; Srivastava, Arun ; van't Riet, Bart ; Jayaram, Hiremagalur N. ; Elford, Howard L. / Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 34, No. 1. pp. 63-66.
@article{c9eb0c0d70b9460cb6946ac39dac3d19,
title = "Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase",
abstract = "Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of ribonucleotide reductase (EC 1.17.4.1) in extracts of L1210 cells by 50{\%} (50{\%} growth-inhibitory concentration, IC50) at 5 μM, whereas hydroxyurea, the only ribonucleotide reductase inhibitor in clinical use, exhibited an IC50 of 500 μM. Ribonucleotide reductase activity was also measured in situ by incubating L1210 cells for 24 h with trimidox at 7.5 μM, a concentration that inhibits cell proliferation by 50{\%} (IC50) or at 100 μM for 2 h; these concentrations resulted in a decrease in enzyme activity to 22{\%} and 50{\%} of the control value, respectively. Trimidox and hydroxyurea were cytotoxic to L1210 cells with IC50 values of 7.5 and 50 μM, respectively. Versus ribonucleotide reductase, trimidox and hydroxyurea yielded IC50 values of 12 and 87 μM, respectively. A dose-dependent increase in life span was observed in mice bearing intraperitoneally transplanted L1210 tumors. Trimidox treatment (200 mg/kg; q1dx9) significantly increased the life span of mice bearing L1210 leukemia (by 82 in male mice and 112{\%} in female mice). The antitumor activity appeared more pronounced in female mice than in male mice. Viewed in concert, these findings suggest that trimidox is a new and potent inhibitor of ribonucleotide reductase and that it is a promising candidate for the chemotherapy of cancer in humans.",
author = "Thomas Szekeres and Kamran Gharehbaghi and Monika Fritzer and Michael Woody and Arun Srivastava and {van't Riet}, Bart and Jayaram, {Hiremagalur N.} and Elford, {Howard L.}",
year = "1994",
month = "1",
doi = "10.1007/BF00686113",
language = "English",
volume = "34",
pages = "63--66",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase

AU - Szekeres, Thomas

AU - Gharehbaghi, Kamran

AU - Fritzer, Monika

AU - Woody, Michael

AU - Srivastava, Arun

AU - van't Riet, Bart

AU - Jayaram, Hiremagalur N.

AU - Elford, Howard L.

PY - 1994/1

Y1 - 1994/1

N2 - Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of ribonucleotide reductase (EC 1.17.4.1) in extracts of L1210 cells by 50% (50% growth-inhibitory concentration, IC50) at 5 μM, whereas hydroxyurea, the only ribonucleotide reductase inhibitor in clinical use, exhibited an IC50 of 500 μM. Ribonucleotide reductase activity was also measured in situ by incubating L1210 cells for 24 h with trimidox at 7.5 μM, a concentration that inhibits cell proliferation by 50% (IC50) or at 100 μM for 2 h; these concentrations resulted in a decrease in enzyme activity to 22% and 50% of the control value, respectively. Trimidox and hydroxyurea were cytotoxic to L1210 cells with IC50 values of 7.5 and 50 μM, respectively. Versus ribonucleotide reductase, trimidox and hydroxyurea yielded IC50 values of 12 and 87 μM, respectively. A dose-dependent increase in life span was observed in mice bearing intraperitoneally transplanted L1210 tumors. Trimidox treatment (200 mg/kg; q1dx9) significantly increased the life span of mice bearing L1210 leukemia (by 82 in male mice and 112% in female mice). The antitumor activity appeared more pronounced in female mice than in male mice. Viewed in concert, these findings suggest that trimidox is a new and potent inhibitor of ribonucleotide reductase and that it is a promising candidate for the chemotherapy of cancer in humans.

AB - Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of ribonucleotide reductase (EC 1.17.4.1) in extracts of L1210 cells by 50% (50% growth-inhibitory concentration, IC50) at 5 μM, whereas hydroxyurea, the only ribonucleotide reductase inhibitor in clinical use, exhibited an IC50 of 500 μM. Ribonucleotide reductase activity was also measured in situ by incubating L1210 cells for 24 h with trimidox at 7.5 μM, a concentration that inhibits cell proliferation by 50% (IC50) or at 100 μM for 2 h; these concentrations resulted in a decrease in enzyme activity to 22% and 50% of the control value, respectively. Trimidox and hydroxyurea were cytotoxic to L1210 cells with IC50 values of 7.5 and 50 μM, respectively. Versus ribonucleotide reductase, trimidox and hydroxyurea yielded IC50 values of 12 and 87 μM, respectively. A dose-dependent increase in life span was observed in mice bearing intraperitoneally transplanted L1210 tumors. Trimidox treatment (200 mg/kg; q1dx9) significantly increased the life span of mice bearing L1210 leukemia (by 82 in male mice and 112% in female mice). The antitumor activity appeared more pronounced in female mice than in male mice. Viewed in concert, these findings suggest that trimidox is a new and potent inhibitor of ribonucleotide reductase and that it is a promising candidate for the chemotherapy of cancer in humans.

UR - http://www.scopus.com/inward/record.url?scp=0028337592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028337592&partnerID=8YFLogxK

U2 - 10.1007/BF00686113

DO - 10.1007/BF00686113

M3 - Article

VL - 34

SP - 63

EP - 66

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -